Laponis Adam 4

What Happened
Adam Laponis, CFO of Twist Bioscience (TWST), reported the sale of 2,597 shares on April 9, 2026. The shares were sold at $49.89 each for a total proceeds of $129,562. The filing indicates these shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units (RSUs), not a discretionary market trade.

Key Details

• Transaction date: 2026-04-09; sale price: $49.89 per share; total proceeds: $129,562.
• Transaction type: Sale (code S) executed as a "sell to cover" to satisfy tax withholding (see footnote F1).
• Footnote F1: Sale was mandated by the issuer’s election under its equity plans to fund tax withholding and does not represent a discretionary trade by the reporting person.
• Filing date / period of report: Filed 2026-04-13 for period of report 2026-04-09. The filing does not indicate a late submission.
• Shares owned after transaction: Not specified in the provided filing summary.

Context
Sell-to-cover transactions are routine when RSUs vest and are commonly executed solely to cover withholding taxes; they generally do not signal a change in the insider’s view of the company. This was not an open-market purchase (which some investors view as a stronger bullish signal).